Items

A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

D. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, May, 2013
FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

D. Yoo, P. Hrycaj, P. Miranda, E. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

C. Hee Suh, A. Berrocal Kasay, E. Chalouhi El-Khouri, P. Miranda, LJ. Božić, S. Jeka, P. Hrycaj, D. Rekalov, P. Wiland, A. Krause, I. Szombati, A. Mihailova, I. Hospodarskyy, M. Piotrowski, S. Ryul Kwon, E. Young Lee, D. Hyun Yoo, W. Park, S. Cheol Shim, S. Joon Lee, T. S. Kwon, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, American college of rheumatology, pp. 100 - 101, Sep, 2016

Items

A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)